First-in-Class cancer drug targets Hard-to-Treat tumors
Disease control
Not yet recruiting
This study tests an experimental oral drug called VMD-102 in people with advanced solid tumors, including liver, lung, kidney, skin (uveal melanoma), and colorectal cancers that have not responded to standard treatments. The drug works by blocking a specific protein (PKC epsilon)…
Phase: PHASE1, PHASE2 • Sponsor: VM Discovery, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC